Bulk Manufacturer of Controlled Substances Application: Usona Institute, 64364 [2018-27132]
Download as PDF
<![CDATA[
64364
Federal Register / Vol. 83, No. 240 / Friday, December 14, 2018 / Notices
(statement of Sen. Tunney). Rather, the
procedure for the public interest
determination is left to the discretion of
the court, with the recognition that the
court’s ‘‘scope of review remains
sharply proscribed by precedent and the
nature of Tunney Act proceedings.’’
SBC Commc’ns, 489 F. Supp. 2d at 11.
A court can make its public interest
determination based on the competitive
impact statement and response to public
comments alone. U.S. Airways, 38 F.
Supp. 3d at 76. See also United States
v. Enova Corp., 107 F. Supp. 2d 10, 17
(D.D.C. 2000) (noting that the ‘‘Tunney
Act expressly allows the court to make
its public interest determination on the
basis of the competitive impact
statement and response to comments
alone’’); S. Rep. No. 93–298 93d Cong.,
1st Sess., at 6 (1973) (‘‘Where the public
interest can be meaningfully evaluated
simply on the basis of briefs and oral
arguments, that is the approach that
should be utilized.’’).
VIII. DETERMINATIVE DOCUMENTS
There are no determinative materials
or documents within the meaning of the
APPA that were considered by the
United States in formulating the
proposed Final Judgment.
Date: December 6, 2018 Respectfully
submitted,
_____
Kenneth A. Libby
Special Attorney
U.S. Department of Justice
Antitrust Division
c/o Federal Trade Commission
600 Pennsylvania Avenue, NW
Washington, DC 20580
Phone: (202) 326–2694
Email: klibby@ftc.gov
[FR Doc. 2018–27055 Filed 12–13–18; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Application: Usona
Institute
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic classes, and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before February 12, 2019.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
DATES:
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
The
Attorney General has delegated his
authority under the Controlled
Substances Act to the Administrator of
the Drug Enforcement Administration
(DEA), 28 CFR 0.100(b). Authority to
exercise all necessary functions with
respect to the promulgation and
implementation of 21 CFR part 1301,
incident to the registration of
manufacturers, distributors, dispensers,
importers, and exporters of controlled
substances (other than final orders in
connection with suspension, denial, or
revocation of registration) has been
redelegated to the Assistant
Administrator of the DEA Diversion
Control Division (‘‘Assistant
Administrator’’) pursuant to section 7 of
28 CFR part 0, appendix to subpart R.
In accordance with 21 CFR
1301.33(a), this is notice that on October
31, 2018, Usona Institute, 2800 Woods
Hollow Road, Madison, Wisconsin
53711 applied to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug code
5-Methoxy-N-N-dimethyltryptamine .................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................
The institute plans to manufacture the
listed controlled substances
synthetically in bulk for use in institutesponsored research.
Dated: December 4, 2018.
John J. Martin,
Assistant Administrator.
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
amozie on DSK3GDR082PROD with NOTICES1
Importer of Controlled Substances
Application: Arizona Department of
Corrections
Notice of application.
Registered bulk manufacturers of
the affected basic class, and applicants
therefore, may file written comments on
or objections to the issuance of the
proposed registration or the proposed
authorization to import on or before
DATES:
VerDate Sep<11>2014
16:57 Dec 13, 2018
Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for hearing must be
sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for hearing
should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
ADDRESSES:
[FR Doc. 2018–27132 Filed 12–13–18; 8:45 am]
ACTION:
January 14, 2019. Such persons may
also file a written request for a hearing
on the application for registration and
for authorization to import on or before
January 14, 2019.
Jkt 247001
Pursuant
to 21 U.S.C. 958(i), the Attorney General
shall, prior to issuing a regulation under
21 U.S.C. 952(a)(2)(B) authorizing the
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
7431
7435
Schedule
I
I
importation of a controlled substance in
schedule I or II, provide manufacturers
holding registrations for the bulk
manufacture of the substance an
opportunity for a hearing. Additionally,
pursuant to 21 CFR 1301.34(a), the
Administrator of the Drug Enforcement
Administration (DEA) shall, upon the
filing of an application for registration
to import a controlled substance in
schedule I or II under 21 U.S.C.
952(a)(2)(B), provide notice and the
opportunity to request a hearing to
manufacturers holding registrations for
the bulk manufacture of the substance
and to applicants for such registrations.
The Attorney General has delegated
his authority under the Controlled
Substances Act,1 including the
provisions codified at 21 U.S.C. 952 and
1 The provisions of federal law relating to the
import and export of controlled substances—those
found in 21 U.S.C. 951 through 971—are more
precisely referred to as the Controlled Substances
Import and Export Act. However, federal courts and
DEA often use the term ‘‘Controlled Substances
Act’’ to refer collectively to all provisions from 21
U.S.C. 801 through 971 and, for ease of exposition,
this document will do likewise.
E:\FR\FM\14DEN1.SGM
14DEN1
]]>Agencies
[Federal Register Volume 83, Number 240 (Friday, December 14, 2018)]
[Notices]
[Page 64364]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-27132]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-392]
Bulk Manufacturer of Controlled Substances Application: Usona
Institute
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic classes, and
applicants therefore, may file written comments on or objections to the
issuance of the proposed registration on or before February 12, 2019.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: The Attorney General has delegated his
authority under the Controlled Substances Act to the Administrator of
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority
to exercise all necessary functions with respect to the promulgation
and implementation of 21 CFR part 1301, incident to the registration of
manufacturers, distributors, dispensers, importers, and exporters of
controlled substances (other than final orders in connection with
suspension, denial, or revocation of registration) has been redelegated
to the Assistant Administrator of the DEA Diversion Control Division
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0,
appendix to subpart R.
In accordance with 21 CFR 1301.33(a), this is notice that on
October 31, 2018, Usona Institute, 2800 Woods Hollow Road, Madison,
Wisconsin 53711 applied to be registered as a bulk manufacturer of the
following basic classes of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
5-Methoxy-N-N-dimethyltryptamine......... 7431 I
Dimethyltryptamine....................... 7435 I
------------------------------------------------------------------------
The institute plans to manufacture the listed controlled substances
synthetically in bulk for use in institute-sponsored research.
Dated: December 4, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2018-27132 Filed 12-13-18; 8:45 am]
BILLING CODE 4410-09-P
